We in Germany are very lucky to be able to prescribe apps actually on prescription. I think it’s with France and Belgium adapting the system, but it’s still a very German thing, so it’s very special. And we applied for being enlisted in this prescribable app setting, which takes another certain step for regulatory approval. It’s a lot of money and time that needs to be invested in this, but I’m hoping that at the end of the year it’s prescribable for all German patients...
We in Germany are very lucky to be able to prescribe apps actually on prescription. I think it’s with France and Belgium adapting the system, but it’s still a very German thing, so it’s very special. And we applied for being enlisted in this prescribable app setting, which takes another certain step for regulatory approval. It’s a lot of money and time that needs to be invested in this, but I’m hoping that at the end of the year it’s prescribable for all German patients. And of course I’m looking forward to collaborating with other countries. And we’re going to also do another study because this was a pilot study with an exploratory view, but now we know the effects and now we’re going to do it with primary and secondary endpoint study. So we need to do another study with more patients, looking also forward if there is somebody who wants to collaborate therefore. But of course my intention in the beginning was to have a better tool to treat patients better, better in non-pharmacological ways. And I think we proved that and we showed the effect. And now it’s all about finding partners who want to bring it to the population, at least in Germany and hopefully in other countries too.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
